Kevin Charles  Gorman net worth and biography

Kevin Gorman Biography and Net Worth

Kevin C. Gorman, Ph.D., is a founder and has been employed with the Company since 1993. Dr. Gorman was appointed President and Chief Executive Officer in January 2008 after serving as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He has served on the Board of Directors since January 2008. Dr. Gorman is also a director of Xencor, Inc., a clinical-stage biopharmaceutical company. From 1990 until 1993, Dr. Gorman was a principal at Avalon Medical Partners, L.P., where he was responsible for the early-stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in Immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.

What is Kevin Charles Gorman's net worth?

The estimated net worth of Kevin Charles Gorman is at least $57.44 million as of February 13th, 2024. Dr. Gorman owns 514,596 shares of Neurocrine Biosciences stock worth more than $57,439,206 as of October 10th. This net worth evaluation does not reflect any other assets that Dr. Gorman may own. Additionally, Dr. Gorman receives an annual salary of $2,050,000.00 as CEO at Neurocrine Biosciences. Learn More about Kevin Charles Gorman's net worth.

How old is Kevin Charles Gorman?

Dr. Gorman is currently 66 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. Learn More on Kevin Charles Gorman's age.

What is Kevin Charles Gorman's salary?

As the CEO of Neurocrine Biosciences, Inc., Dr. Gorman earns $2,050,000.00 per year. Learn More on Kevin Charles Gorman's salary.

How do I contact Kevin Charles Gorman?

The corporate mailing address for Dr. Gorman and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Kevin Charles Gorman's contact information.

Has Kevin Charles Gorman been buying or selling shares of Neurocrine Biosciences?

Kevin Charles Gorman has not been actively trading shares of Neurocrine Biosciences over the course of the past ninety days. Most recently, Kevin Charles Gorman sold 2,832 shares of the business's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $133.02, for a transaction totalling $376,712.64. Following the completion of the sale, the chief executive officer now directly owns 514,596 shares of the company's stock, valued at $68,451,559.92. Learn More on Kevin Charles Gorman's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 48 times. They sold a total of 592,855 shares worth more than $80,092,533.10. The most recent insider tranaction occured on August, 15th when Director William H Rastetter sold 14,250 shares worth more than $2,090,332.50. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 8/15/2024.

Kevin Charles Gorman Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2024Sell2,832$133.02$376,712.64514,596View SEC Filing Icon  
2/8/2024Sell2,274$134.15$305,057.10506,962View SEC Filing Icon  
2/6/2024Sell3,040$142.18$432,227.20504,919View SEC Filing Icon  
1/31/2024Sell2,707$140.69$380,847.83502,188View SEC Filing Icon  
1/8/2024Sell105,835$132.44$14,016,787.40499,754View SEC Filing Icon  
8/21/2023Sell9,328$107.40$1,001,827.20499,754View SEC Filing Icon  
2/8/2023Sell2,274$104.30$237,178.20491,365View SEC Filing Icon  
2/6/2023Sell3,040$105.68$321,267.20468,008View SEC Filing Icon  
1/31/2023Sell2,707$110.08$297,986.56465,278View SEC Filing Icon  
2/7/2022Sell8,710$80.82$703,942.20View SEC Filing Icon  
2/8/2021Sell10,466$116.75$1,221,905.50443,249View SEC Filing Icon  
2/5/2021Sell2,422$114.16$276,495.52443,249View SEC Filing Icon  
1/8/2021Sell308,250$110.22$33,975,315.00584,520View SEC Filing Icon  
11/12/2020Sell3,390$90.78$307,744.20441,071View SEC Filing Icon  
8/5/2020Sell3,390$118.91$403,104.90438,021View SEC Filing Icon  
4/24/2020Sell2,906$99.45$289,001.70434,971View SEC Filing Icon  
2/7/2020Sell3,248$103.35$335,680.80432,357View SEC Filing Icon  
2/5/2020Sell5,449$103.09$561,737.41423,351View SEC Filing Icon  
8/8/2019Sell80,000$95.31$7,624,800.00468,508View SEC Filing Icon  
8/6/2019Sell50,911$95.15$4,844,181.65468,508View SEC Filing Icon  
2/5/2019Sell7,614$88.16$671,250.24408,082View SEC Filing Icon  
5/1/2018Sell126,832$80.75$10,241,684.00473,865View SEC Filing Icon  
2/6/2018Sell105,983$80.25$8,505,135.75339,482View SEC Filing Icon  
1/16/2018Sell3,750$78.89$295,837.50View SEC Filing Icon  
5/2/2017Sell21,739$53.23$1,157,166.97354,346View SEC Filing Icon  
4/12/2017Sell19,596$50.42$988,030.32332,913View SEC Filing Icon  
2/6/2017Sell3,010$43.18$129,971.80250,542View SEC Filing Icon  
2/3/2017Sell3,125$42.55$132,968.75247,802View SEC Filing Icon  
1/17/2017Sell3,750$40.65$152,437.50244,677View SEC Filing Icon  
1/10/2017Sell3,750$43.28$162,300.00240,927View SEC Filing Icon  
2/3/2016Sell3,125$38.04$118,875.00228,077View SEC Filing Icon  
1/19/2016Sell3,750$46.70$175,125.00224,952View SEC Filing Icon  
1/11/2016Sell3,750$44.17$165,637.50221,202View SEC Filing Icon  
10/16/2015Sell33,500$47.77$1,600,295.00217,452View SEC Filing Icon  
3/24/2015Sell40,000$41.53$1,661,200.00View SEC Filing Icon  
1/16/2015Sell3,750$30.79$115,462.50View SEC Filing Icon  
1/12/2015Sell3,750$28.43$106,612.50View SEC Filing Icon  
1/8/2015Sell25,000$27.39$684,750.00View SEC Filing Icon  
12/19/2014Sell70,000$23.41$1,638,700.00View SEC Filing Icon  
1/10/2014Sell3,750$18.57$69,637.50180,952View SEC Filing Icon  
1/7/2014Sell108,000$16.76$1,810,080.00177,202View SEC Filing Icon  
See Full Table

Kevin Charles Gorman Buying and Selling Activity at Neurocrine Biosciences

This chart shows Kevin Charles Gorman's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $111.80
Low: $111.14
High: $112.57

50 Day Range

MA: $131.04
Low: $111.66
High: $153.15

2 Week Range

Now: $111.80
Low: $103.63
High: $157.98

Volume

159,138 shs

Average Volume

852,197 shs

Market Capitalization

$11.25 billion

P/E Ratio

30.80

Dividend Yield

N/A

Beta

0.36